Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nikethamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.52 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.49 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.49 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nikethamide SCHEMBL246456 | 0.98 | HTT (0.65) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL29754232 | 0.98 | HTT (0.65) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL28425770 | 0.97 | HTT (0.63) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL11145071 | 0.93 | HTT (0.64) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL5964875 | 0.91 | F7 (0.67) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL9541686 | 0.91 | HTT (0.57) | HTTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL14855190 | 0.87 | HTT (0.61) | HTTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL10599239 | 0.87 | HTT (0.57) | HTTALDH1A1LMNAKDM4EHPGD | |
| Hydrochloric Acid SCHEMBL30055763 | 0.85 | HTT (0.61) | HTTALDH1A1LMNAKDM4ENPSR1 | |
| SCHEMBL28527737 | 0.85 | HTT (0.57) | HTTALDH1A1LMNAKDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230323149-A1 | Reaction Solution For Pigment Printing, Ink Set, And Recording Method | SEIKO EPSON CORPORATION (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230313451-A1 | Recording Method | SEIKO EPSON CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4239032-A1 | REACTION SOLUTION FOR PIGMENT PRINTING, INK SET, AND RECORDING METHOD | Seiko Epson Corporation (JP) | 2023-09-06 | — | — | EP | disclosed |
| EP-4239123-A1 | RECORDING METHOD | Seiko Epson Corporation (JP) | 2023-09-06 | — | — | EP | disclosed |
| US-11667805-B2 | Processing liquid composition, composition set, processing method, and textile printing method | SEIKO EPSON CORPORATION | 2023-06-06 | — | — | US | disclosed |
| WO-2021240914-A1 | URINE SEDIMENT STAINING LIQUID | 東洋紡株式会社 | 2021-12-02 | — | — | WO | disclosed |
| EP-3228632-A1 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE | Kawakami, Koji (JP) | 2017-10-11 | — | — | EP | disclosed |
| EP-3228633-A1 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE | Kawakami, Koji (JP) | 2017-10-11 | — | — | EP | disclosed |
| EP-2370107-B1 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE | KAWAKAMI KOJI (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-8940862-B2 | Selective anticancer chimeric peptides which bind transferrin receptor | Kawakami, Koji (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940863-B2 | Selective anticancer chimeric peptides which bind neuropilin receptor | Kawakami, Koji (JP) | 2015-01-27 | — | — | US | disclosed |
| US-20130274201-A1 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE | UPSTREAM INFINITY, INC. (JP) | 2013-10-17 | — | — | US | disclosed |
| US-20130274200-A1 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE | UPSTREAM INFINITY, INC. (JP) | 2013-10-17 | — | — | US | disclosed |
| US-8436137-B2 | Selective anticancer chimeric peptide comprising an EGF receptor-binding peptide and a cytotoxic peptide | Kawakami, Koji (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20110319336-A1 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE | UPSTREAM INFINITY, INC. (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2370107-A2 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE | Upstream Infinity, Inc. (JP) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010064207-A2 | SELECTIVE ANTICANCER CHIMERIC PEPTIDE | KAWAKAMI KOJI (JP) | 2010-06-10 | — | — | WO | disclosed |